3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Carcinoma, Renal Cell
59
Gastrointestinal Stromal Tumors
22
Neoplasms
18
Breast Neoplasms
16
Kidney Neoplasms
12
Carcinoma, Non-Small-Cell Lung
11
Carcinoma
7
Colorectal Neoplasms
6
Neoplasm Metastasis
5
Stomach Neoplasms
4
Neuroendocrine Tumors
4
Kidney Diseases
4
Gastrointestinal Neoplasms
4
Clear-cell metastatic renal cell carcinoma
4
Carcinoma, Hepatocellular
4
Adenoma, Islet Cell
4
Prostatic Neoplasms
3
Urologic Neoplasms
2
Urogenital Neoplasms
2
Pancreatic Neoplasms
2
Lung Neoplasms
2
Financial Stress
2
Urothelial Cancer
1
Urologic Diseases
1
Thyroid Neoplasms
1
Somatostatinoma
1
Solid Tumors
1
Solid Tumor
1
Primary hyperoxaluria type 2
1
Patient Preference
1
Interventions
lutetium Lu 177 dotatate
3
Octreotide
3
pasireotide
2
lanreotide
2
amino-acid, glucose, and electrolyte solution
2
Everolimus
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
famitinib
1
copper dotatate CU-64
1
arginyllysine
1
Temozolomide
1
Sunitinib
1
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
PM 01183
1
Oxaliplatin
1
Lutetium-177
1
Lutetium
1
Leucovorin
1
Irinotecan
1
Folfox protocol
1
Fluorouracil
1
E-7386
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Gastro-enteropancreatic neuroendocrine tumor
×
Sunitinib
×
Clear all
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled